Claire McCaskill actually said...
Well, what I am saying is that they could be reassigned to a plan that is going to cost the U.S. Government more than it should because that particular plan has not negotiated a good deal with a given drug company that particular recipient might need more of.
Context
Highlighting potential inefficiencies in Medicare plan assignments.
03/02/2010